Brain

Prime Biome Reviews Controversy Disclosure Report: Surprising Facts and Figures Revealed

ST. PETERSBURG, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- In today's fast-paced world, guts and skin health has become a…

10 months ago

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

These candidates, previously shown to be active in vitro against respiratory syncytial virus (RSV) and human parainfluenza virus 3 (hPIV3),…

10 months ago

NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference

MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming…

10 months ago

Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma

SAN DIEGO and LOS ANGELES, March 26, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage…

10 months ago

Belay Diagnostics Partners with GenomOncology to Support High-Performance Liquid Biopsy Test for Central Nervous System Cancer Detection

CLEVELAND, March 25, 2025 /PRNewswire/ -- Belay Diagnostics announces its partnership with GenomOncology (GO), a precision medicine software company that provides…

10 months ago

Linus Health to Present New Research Findings at Leading Alzheimer’s and Parkinson’s Conference

AD/PD™ 2025 to feature presentations on Linus Health's digital cognitive health assessments, plus attendees can learn more about company's recent…

10 months ago

DeepIntent Unveils DeepIntent Cortex™, Ushering in the Next Generation of Healthcare Demand Side Platforms

NEW YORK, March 25, 2025 /PRNewswire/ -- DeepIntent, the leading healthcare advertising technology company, today introduced DeepIntent Cortex, its most…

10 months ago

Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity

Helicore’s first-in-human study is designed to evaluate the safety and tolerability of HCR-188 in a single and multiple ascending dose…

10 months ago

NervGen Pharma to Host Virtual Investor Event

Key opinion leaders and company management will discuss the current spinal cord injury treatment landscape and NervGen's Phase 1b/2a clinical…

10 months ago

Epilepsy Foundation of America Harnesses the “Power in Purple” for Special Awareness Day

Purple Day® encourages education, support, and advocacy for the epilepsy communityBOWIE, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Join the Epilepsy…

10 months ago